Genable Technologies Ltd secures orphan drug designation by FDA for RP treatment

Genable Technologies Ltd gene therapy product GT038 has been granted orphan drug designation by the Federal Drug Administration (FDA) in the US for the treatment of Retinitis Pigmentosa. This provides Genable Technologies with seven years market exclusivity once GT308 has secured regulatory approval.

GT038 is currently undergoing formal pre-clinical assessments prior to commencing clinical studies in patients. 

For more info:


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: